WO2014054975A3 - Composition pharmaceutique possédant une activité métabolique, anti-cataracte et rétinoprotectrice (et variantes) - Google Patents

Composition pharmaceutique possédant une activité métabolique, anti-cataracte et rétinoprotectrice (et variantes) Download PDF

Info

Publication number
WO2014054975A3
WO2014054975A3 PCT/RU2013/000806 RU2013000806W WO2014054975A3 WO 2014054975 A3 WO2014054975 A3 WO 2014054975A3 RU 2013000806 W RU2013000806 W RU 2013000806W WO 2014054975 A3 WO2014054975 A3 WO 2014054975A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
cataract
retina
metabolic
taurine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/RU2013/000806
Other languages
English (en)
Russian (ru)
Other versions
WO2014054975A2 (fr
Inventor
Владимир Павлович ЛОБКО
Олег Олегович ТИХОНЕНКО
Анастасия Геннадьевна ЧЕЛЯЕВА
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2014054975A2 publication Critical patent/WO2014054975A2/fr
Publication of WO2014054975A3 publication Critical patent/WO2014054975A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/44—Elemental carbon, e.g. charcoal, carbon black
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention appartient au domaine de la médecine et notamment de l'ophtalmologie. L'objectif visé par la présente invention est la création d'une composition pharmaceutique efficace possédant une action métabolique, anti-cataracte, rétinoprotectrice grâce au fait que la composition pharmaceutique contient de la taurine et, de plus, des substances minérales ainsi que les isotopes 13C, 34S. La mise en oeuvre des compositions pharmaceutiques de l'invention permet d'assurer un meilleur effet thérapeutique et d'accélérer la survenance de l'effet thérapeutique sans augmenter la concentration de taurine, et d'augmenter la stabilité de la composition pharmaceutique contenant la taurine pendant toute la durée de vie.
PCT/RU2013/000806 2012-10-01 2013-09-17 Composition pharmaceutique possédant une activité métabolique, anti-cataracte et rétinoprotectrice (et variantes) Ceased WO2014054975A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EA201201218 2012-10-01
EA201201218A EA020361B1 (ru) 2012-10-01 2012-10-01 Фармацевтический состав, содержащий магний, железо, цинк и обладающий метаболическим, противокатарактным, ретинопротекторным действием (варианты)

Publications (2)

Publication Number Publication Date
WO2014054975A2 WO2014054975A2 (fr) 2014-04-10
WO2014054975A3 true WO2014054975A3 (fr) 2014-06-12

Family

ID=50435549

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU2013/000806 Ceased WO2014054975A2 (fr) 2012-10-01 2013-09-17 Composition pharmaceutique possédant une activité métabolique, anti-cataracte et rétinoprotectrice (et variantes)

Country Status (2)

Country Link
EA (1) EA020361B1 (fr)
WO (1) WO2014054975A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025005662A2 (fr) * 2023-06-27 2025-01-02 김천균 Composition de gouttes oculaires pour le traitement et la prévention de maladies oculaires et son procédé de préparation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA008591B1 (ru) * 2002-12-31 2007-06-29 Пфайзер Продактс Инк. Производные 3-(3,5-диоксо-4,5-дигидро-3h-(1,2,4)триазин-2-ил)бензамида в качестве ингибиторов p2xдля лечения воспалительных заболеваний

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA008591B1 (ru) * 2002-12-31 2007-06-29 Пфайзер Продактс Инк. Производные 3-(3,5-диоксо-4,5-дигидро-3h-(1,2,4)триазин-2-ил)бензамида в качестве ингибиторов p2xдля лечения воспалительных заболеваний

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"RLS-2006", REGISTR LEKARSTVENNYKH SREDSTV ROSSII. ENTSIKLOPEDIA LEKARSTV, vol. 14, 2005, VYPUSK. MOSKVA, pages 769 *
CHELIAEVA A. G., MINERALNYE VESHCHESTVA, 24 September 2011 (2011-09-24), Retrieved from the Internet <URL:http:icfond.ra/servises/item/minelal-vechestva?categoryid=1> *
CHEN K. ET AL.: "Taurine protects transtormed rat retinal ganglion cells from hypoxia-induced apoptosis by preventing mitochondrial dysfunction.", BRAIN RES., vol. 1279, 7 July 2009 (2009-07-07), pages 131 - 8 *
DATABASE PMID accession no. 9427840 *
LOBKO V. P. ET AL.: "Nano-kavitatsionnaya tekhnologia obogashchenia veshchestv izotopom ugleroda", 22 September 2011 (2011-09-22), Retrieved from the Internet <URL:http:icfond.ra/servises/item/nano-cavitac?category_id=l>> *

Also Published As

Publication number Publication date
EA201201218A1 (ru) 2014-04-30
WO2014054975A2 (fr) 2014-04-10
EA020361B1 (ru) 2014-10-30

Similar Documents

Publication Publication Date Title
EA201500535A1 (ru) Применение akkermansia muciniphila для лечения метаболических расстройств, увеличения расхода энергии и насыщения, снижения веса, композиция, фармацевтическая композиция, косметическая композиция и лекарственное средство
EA201201658A1 (ru) Производные пиперидина и их применение для лечения метаболических нарушений
EA201400771A1 (ru) Новые производные азетидина, фармацевтические композиции и их применение
IN2014DN09434A (fr)
WO2014062720A3 (fr) Méthodes de traitement du cancer
WO2014062733A3 (fr) Composés de benzène substitué
EP3682875A3 (fr) Méthodes de traitement du syndrome métabolique pédiatrique
EA028156B9 (ru) Конденсированные гетероциклические соединения в качестве модуляторов ионных каналов
EA201391033A1 (ru) Ингибиторы bace-2 для лечения метаболических расстройств
PH12013502240B1 (en) Novel compounds as modulators of protein kinase
HK1198475A1 (en) Heterocyclic compounds and uses thereof
CL2014001437A1 (es) Compuestos derivados de aril dihidropiridinona y piperidinona como inhibidores de monoacilglicerol aciltransferasa (mgat2); composicion y combinacion farmaceutica; y uso en el tratamiento y prevencion de diabetes, hiperglucemia, retinopatia, sindrome metabolico, entre otras enfermedades.
MY162146A (en) Pharmaceutical composition
MX340985B (es) Compuestos de n-heteroarilo.
GEP201706621B (en) Benzamides
EA201591180A1 (ru) Составы ингибитора lfa-1
MX2015000179A (es) Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas.
EA201590564A1 (ru) Стабильные составы
BR112015012986A2 (pt) composições e métodos de uso
WO2014054975A3 (fr) Composition pharmaceutique possédant une activité métabolique, anti-cataracte et rétinoprotectrice (et variantes)
WO2014011077A3 (fr) Composition pharmaceutique ayant une action métabolique anti-cataracte et de protection de la rétine, et variantes
EA201491455A1 (ru) ЭФФЕКТОРЫ β-АРРЕСТИНА, КОМПОЗИЦИИ, ИХ СОДЕРЖАЩИЕ, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
NZ629475A (en) Pharmaceutical composition comprising benzyl alcohol for the treatment of migraines
MX2013006332A (es) Composiciones farmaceuticas orales para uso en dislipidemias.
WO2013129977A3 (fr) Composition pharmaceutique pour injections possédant une activité neuroprotectrice, anti-amnésique, antioxydante, anti-hypoxique et anti-ischémique (et variantes)

Legal Events

Date Code Title Description
122 Ep: pct application non-entry in european phase

Ref document number: 13843104

Country of ref document: EP

Kind code of ref document: A2